Wednesday, 18 October 2017

BioLargo's Clyra Medical Division 510(k) Application with FDA Offers New Technology for Advanced Wound Care - Tamarack Article

Article By: Tamarack Advisors. 
For a direct link to the article by Tamarack Advisors-
Go to the Accesswire link here!

The need for effective wound care products has never been greater. Growing global population, rapidly increasing antimicrobial resistance, and the diabetes epidemic among other things, are making it difficult for healthcare providers to effectively treat wounds, putting a strain on patients and also on healthcare systems. Medical professionals are constantly on the lookout for new and innovative methods to help heal difficult-to-treat or chronic wounds, resulting in an $18B market for advanced wound care products.










One such solution is poised to be offered by BioLargo, Inc. (OTC: BLGO) subsidiary, Clyra Medical Technologies. On September 22nd, BioLargo, Inc. (OTC: BLGO)  announced that Clyra submitted an FDA 510(k) application for an advanced wound care product. Clyra has developed a wound care formulation that integrates the well-understood staple of antimicrobial iodine into a revolutionary new product that is more effective yet gentler than current solutions. Additionally, Clyra’s product produces no known antimicrobial resistance and has shown sustained antimicrobial power for up to 3 days.

Iodine has been the considered a gold standard antimicrobial for nearly two hundred years. However, traditional iodine products contain high, toxic levels of iodine, which can be damaging to fibroblasts and delay wound healing. Consequently, physicians consider traditional iodine products as a “last resort,” preferring gentler antimicrobial treatments for managing chronic wounds, such as silver, honey, and hypochlorous acid. While these antimicrobials have various proven levels of efficacy, in each case they present some sort of tradeoff in practical use, such as high costs, potential for acquired resistance, cytotoxic implications (damage to skin or other cells), and a limited effective duration.   

A wound care antimicrobial formulated with high efficacy and without the tradeoffs of the most-often prescribed products on the market would be poised to disrupt the advanced wound care industry. That’s exactly what BioLargo’s Clyra Medical Technologies has done. Their product is broad-spectrum, highly effective, and doesn’t have the collateral tissue damage problems of previous iodine-based wound care products. It remains effective longer than traditional antimicrobials, has no-know microbial resistance, and with such a low level of iodine can be offered at lower costs. The Clyra product creates a wound environment that is much more amenable to healing and regeneration. Consequently, Clyra’s wound care product has the potential to provide immense benefit in innumerable chronic or difficult-to-treat wound situations, and Clyra anticipates having a big impact on the very competitive $18B advanced wound care market.

Clyra management reports that after years of development work, they have developed a proprietary technology that retains the full power of iodine, yet minimizes skin tissue damage so that the products can remain non-cytotoxic. While Clyra’s products will likely feature additional technical claims, features and benefits, its broad spectrum and sustained antimicrobial performance (including biofilm), coupled with its safety profile and low cost, distinguish it from alternative products.

In June, Clyra presented their breakthrough technology at the 15th annual Peter Sheehan Wound Healing: Science & Industry Conference in Puerto Rico, attended by leading wound care clinicians and researchers. We had a chance to speak with Clyra Medical President, Steve Harrison, about the new technology. He commented, "We are highly encouraged by the overwhelming positive response from the clinical wound care experts attending the conference. The data from the FDA pre-submission testing generated a great deal of enthusiasm among the leading clinicians and researchers at the conference.”

The presentation at the conference highlighted Clyra's advantages over existing wound care products:
  • Clyra's hydrogel wound dressings are highly effective and have no known microbial resistance.
  • GLP lab studies demonstrated sustained release and continued antimicrobial effectiveness against major organisms.
  • In vivo pig studies have shown effectiveness against mature biofilm, with better results than certain prescription antimicrobial solutions.
  • Non-cytotoxic, non-sensitizing, and safe to human cells.
  • Can easily integrate Clyra technologies into existing products and new ones in the pipeline, including regenerative tissue.

Dr. Brock Liden, DPM, a wound care expert with an extensive wound and limb salvage practice in Ohio, presented the latest Clyra data to the conference. He commented, "When I was introduced to the Clyra technology, I was very interested to learn more. This is a complex that has been shown to impact bacteria, and shows sustained activity, yet be safe to cells and the wound healing process. It may have clinical application to be used with cellular tissue products, stem cells, and growth factors with no harm to the modality. This is a significant breakthrough in the wound space. With further clinical research we may even have a modality to impact established biofilms while doing no harm to the host or the healing modalities being utilized. As I learn more about Clyra's technology, I feel that it has the potential to have a significant impact in wound care, as well as potential in other areas of medicine."

Mr. Harrison continued, “In keeping with BioLargo’s mission, our advanced wound care products have an important contribution to Make Life Better as we compete for a segment of the $18 billion global advanced wound care market. Our products are safe, gentle, and effective, and as such, we believe their role in infection control, chronic wound management and regenerative skin therapy are important and valuable. We are targeting early 2018 to be ready for market.”
Clyra is keenly aware of the competition they will face in the wound care industry.  One established competitor offering a broad line of antimicrobial wound care products including silver and iodine based offerings is Smith & Nephew (NYSE: SNN). Another competitor is Derma Sciences (honey), now owned by Integra LifeSciences Holdings Company (NASDAQ: IART). Senior Strategy Advisor to Clyra Medical, Tanya Rhodes, Ph.D., was the former Smith & Nephew Vice President of Innovation and Vice President at Smith & Nephew Wound Management. Dr. Rhodes invested 15 years at Smith & Nephew U.S., and more than 20 years in the wound management and skin care industry globally. She has established a broad base of expertise that includes a concept-to-commercialization philosophy utilizing product design, strategic marketing and evidence-based trials as well as reimbursement and regulatory compliance strategies. Over her career, she played an instrumental role in bringing a number of staple wound care technologies to market around the globe.
Management tells us that several additional products are in the pipeline and expected to follow.  Clyra’s wound care products’ data will also be presented at the upcoming SAWC (Symposium on Advanced Wound Care) fall meeting held in Las Vegas on October 20-22, 2017.
















About BioLargo, Inc.
BioLargo, Inc. is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.
Legal Disclaimer:


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

Tuesday, 17 October 2017

BioLargo Wins OCTANe OC High Tech Innovation Award!

We announced earlier this year that we were made a finalist for an industry innovation award given by Orange County's premier tech incubator, OCTANe - today we are happy to confirm that BioLargo won a High Tech Innovation award in the category of "Best: Horizontal Disruption"! This is a great honor for our company, and we think it heralds significant growth and adoption of our various innovative technology platforms: our AOS water treatment system, CupriDyne Clean Industrial Odor Eliminator, Clyra Medical Technologies, and the iSAN iodine dosing system.








To learn more about this award, read our press release here! This was the 24th annual OCTANe High Tech Innovation award program, and we are proud to have received this honor.

The award recognizes BioLargo's strength in developing disruptive technology solutions for a wide range of high-growth markets simultaneously. The term "horizontal disruption" denotes a business strategy where a company expands the use of an innovative, disruptive technology to affect (and displace) multiple non-overlapping markets or revenue streams - as opposed to vertical disruption, where a technology is leveraged to own a greater share of a single "vertical" value chain in one market. You can learn more about these concepts here and here!

Some of the other winners of this year's High Tech Innovation Awards included some big names in Southern Californian tech innovation, including HyperX, a juggernaut in computer components and video gaming peripherals.

  • HyperX
  • Alteryx
  • Arbitech
  • MeU CARE
  • CiE Digital Labs
  • Sonendo
  • IN CIRCL
  • Swift Engineering
  • Vertos Medical
  • Birch Street Systems

Friday, 29 September 2017

BioLargo’s Medical Subsidiary Files 510(k) with FDA for its Novel Wound Care Technology

Westminster, CA (Uptick Newswire – September 28, 2017) – BioLargo, Inc. (OTCQB:BLGO), a sustainable science and technology company that delivers practical solutions for clean water, clean air, and advanced wound care, announced today its subsidiary Clyra Medical Technologies had submitted to the Food & Drug Administration an application for premarket notification under Section 510(k) of the Food, Drug, and Cosmetic Act. By statute, Clyra must wait 90 days prior to going to market while the FDA evaluates the submission and determines whether to grant it clearance.







BioLargo also announced that the new technology and related data will be exhibited at the Symposium on Advanced Wound Care/Fall (SAWC/Fall), October 20 – 22, 2017, in Las Vegas, Nevada (http://www.sawc.net/fall/). The semi-annual SAWC meeting is the premier interdisciplinary wound care program and the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, researchers, and scientists are expected to attend the 2017 SAWC/Fall meeting.
Clyra Medical President Steve Harrison commented, “In keeping with BioLargo’s mission, our advanced wound care products have an important contribution to Make Life Better for those suffering with a wide variety of wounds. Our products are safe, gentle and effective, and as such, we believe their role in infection control, chronic wound management, and regenerative skin therapy are important and valuable. We hope this FDA submission is the first of many that will allow us to bring Clyra products to the Advanced Wound Care market.”
President & CEO of BioLargo, Dennis P. Calvert commented, “This very important milestone is another example of our dedication to build value for our shareholders. This project has required an army of supporters, investors, and a highly qualified technical team to make our vision for these products a reality. Through Clyra Medical we will serve others in a very high value market and we believe these platform products will play an important role in health care for decades to come.”
About BioLargo, Inc.
BioLargo, Inc. is a sustainable science, technology and full-service environmental engineering company that makes life better by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air and advanced wound care. More information can be found about the company at www.BioLargo.com. Its engineering division (www.BioLargoEngineering.com) features an exceptional team of experienced specialists dedicated to integrity, reliability, safety, and environmental stewardship. It water division (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous contaminants in water in a fraction of the time and cost of current technologies. Its odor division features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that that contends with malodors, VOC’s or similar air quality related problems. Its personal care product division features products in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). Its medical division (www.ClyraMedical.com) focuses on advanced wound care management, featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control and regenerative tissue therapy. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc (www.ClarionWater.com).                    
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2
Source: Uptick Newswire

Wednesday, 20 September 2017

Uptick Newswire Interview with Dennis Calvert - Sept 20, 2017



Dennis Calvert, CEO of BioLargo, Inc. (BLGO) was invited for another interview for Uptick Newswire Stock Day Podcast with host Everett Jolly. The main topic of the interview was BioLargo's recent creation of an engineering subsidiary called BioLargo Engineering, Science & Technologies, LLC. Dennis explained the financing the company secured to accelerate the new venture from Lincoln Park Capital. The new engineering company represents a huge expansion of BioLargo's technical capabilities, and will allow the company to take part in a myriad of commercial opportunities in the engineering services sector, as well as provide an effective mechanism for engineering and scaling-up BioLargo's AOS water treatment platform.

Dennis also gave listeners an update on CupriDyne Clean's growing commercial success, with its three national purchasing agreements with major national waste handling companies. Finally, he described BioLargo's huge opportunities in the advanced wound care market, with two Clyra Medical products soon applying for FDA 510(K) registration. These products will provide effective, safe, and gentle solutions for infection control, chronic wound therapy, and regenerative tissue therapy.

Thursday, 14 September 2017

BioLargo Starts World-Class Engineering Division and Secures New Financing to Accelerate Commercialization of its Disruptive Technology in $860B Global Water Market

For a direct link to the article, by Tamarack Advisors, go here



After a decade of diligent R&D effort supported by a loyal base of investors, BioLargo, Inc. (OTCQB: BLGO) has built an expansive suite of intellectual property for disruptive technologies focused on clean water, clean air and advanced wound care. Its AOS (Advanced Oxidation System) is billed as the high performance and low cost water treatment option for rapid water disinfection and concurrent decontamination, representing a technical leap forward in advanced water treatment. Just one week ago we covered their third annual technical symposium for the AOS, where results of commercial validation studies done with three
separate wastewaters in collaboration with a leading water-engineering firm confirmed not only the commercial viability of the AOS, but also its superior technical and economic performance metrics.

Only a week later, BioLargo made a surprise press release announcing the hiring of a world-class engineering team and the formation of a new services division called BioLargo Engineering, Science & Technologies, LLC.

The new subsidiary will be headquartered in the Knoxville, Tennessee area and its team will be led by Mr. Randall P. Moore, an executive-level engineer with more than 30 years of industrial and commercial experience, most recently as Manager of Operations for Consulting and Engineering for the Knoxville, Tennessee office of Chicago Bridge & Iron (CB&I) Environmental & Infrastructure, Inc. Mr. Moore has worked with the newly recruited team at BioLargo Engineering Science & Technologies for the past 10 plus years while at CB&I. Mr. Moore commented, “BioLargo’s various technologies have an important and significant commercial opportunity to serve clients around the world. Our entire team is excited to be part of such an innovative and purposeful company as BioLargo.”

BioLargo’s new engineering team has more than 200+ combined years of industry experience, and will immediately pursue business opportunities to provide engineering services around the world, supported by BioLargo’s new Director of Business Development Dr. Shan Yong. A list of BioLargo Engineering’s offered services can be found on their website. Equally important, the new BioLargo Engineering team provides a valuable bridge to new client relationships for BioLargo.

The question on everyone’s mind: what does this new subsidiary mean for BioLargo’s flagship technology, the AOS?

From all accounts, the new team has the technical experience and know-how to scale-up and engineer the AOS to meet the needs of industrial end-users. Importantly, having this talent in-house rather than outsourcing it means that BioLargo will have increased freedom to expand its intellectual property. BioLargo now has access to robust engineering and design capabilities, and considering the depth of talent at BioLargo Engineering, Science & Technologies, LLC, BioLargo will likely have new opportunities reaching beyond their current technical assets.

To help provide growth capital to the Company and assist in the new venture, BioLargo has entered into a common stock purchase agreement with Lincoln Park Capital for up to $10 million of equity capital, priced at the market, and subject to certain terms and conditions as described in the company’s 8-k. According to the terms of the purchase agreement, and subject to a registration statement being filed and declared effective by the Securities and Exchange Commission, BioLargo will have the sole discretion to sell common stock to LPC over a 36-month period at times that are controlled by BioLargo and in amounts as described in the purchase agreement. No warrants, derivatives, financial or business covenants are associated with the agreement and LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging in BioLargo’s common stock.

BioLargo’s president, Dennis P. Calvert, commented, “With our proven high impact, low cost AOS Water treatment system, and with over 200 combined years of commercial engineering experience serving a wide range of industrial clients, combined with funding from Lincoln Park Capital, we are well positioned to serve a wide range of clients with environmental engineering services as well propel our AOS technologies from the lab to commercial clients.”



Monday, 11 September 2017

BioLargo Acquires World-Class Engineering Team to Form a New Engineering Services Subsidiary and Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital

Westminster, CA , Sept. 11, 2017 (GLOBE NEWSWIRE) -- BioLargo, Inc. (OTCQB:BLGO, “Company”), a sustainable science and technology company that delivers practical solutions for clean water, clean air and advanced wound care, announced today it finalized the terms of employment with seven veteran scientists and engineers to work with and lead its newly formed subsidiary, BioLargo Engineering, Science & Technologies, LLC. While serving clients with its robust environmental engineering capabilities, it will also combine its talents with BioLargo’s existing research team to innovate and commercialize the Company’s technology platforms, including its AOS system. The Company also announced a purchase agreement for up to $10 million with Lincoln Park Capital (“LPC”), pursuant to which it may sell shares of its common stock to LPC as described below and more fully in the Company’s Form 8-K previously filed.
BioLargo’s president, Dennis P. Calvert, commented “With over 200 years of commercial engineering experience serving a wide range of industrial clients, and funding from Lincoln Park Capital, we are well positioned to serve a wide range of clients with environmental engineering services as well propel our AOS technologies from the lab to commercial clients.”
BioLargo’s new engineering team has extensive experience serving a wide range of industrial clients ranging from chemical engineering, wastewater treatment (including design, operations, data gathering and data evaluation), process safety, energy efficiency, air pollution, design and control, technology evaluation, technology integration, air quality management & testing, engineering management, permitting, industrial hygiene, applied research and development, air testing, environmental permitting, HAZOP review, chemical processing, thermal design, computational fluid dynamics, mechanical engineering, mechanical design, NEPDES permitting, RCRA/TSCA compliance and permitting,  project management, storm water design & permitting, marine engineering, AutoCAD, bench chemistry, continuous emission monitoring system operator, data handling and evaluation and decommissioning and decontamination of radiological and chemical contaminated facilities.
The new subsidiary will be headquartered in the Knoxville, Tennessee area and its team will be led by Mr. Randall P. Moore. Operations will begin immediately. Mr. Moore is an engineer/executive with more than 30 years of industrial and commercial experience, most recently as Manager of Operations for Consulting and Engineering for the Knoxville, Tennessee office of CB&I Environmental & Infrastructure, Inc. Before that, from February 2013 – May 2017, he was the Manager of Operations at Integrated Environmental Solutions a Consulting and Engineering group within CB&I, Environmental and Infrastructure, Inc. He led the IES Group to identify, develop and commercialize emerging technologies and apply those technologies to recalcitrant environmental issues in the industrial sector. Before that, from September 2006 – September 2012, he was the Office Director Knoxville Tennessee – Responsible for all office functions for 175-person office. From May 2002 – February 2013, Business Line Manager, Commercial Consulting and Engineering at Shaw Environmental & Infrastructure (Shaw E & I). Before that, he served as a technical staff consultant, manager of field engineering and air quality services, and project engineer. From 1980 - 1984, he was a Co-op Engineering Technician at Oak Ridge Gaseous Diffusion Plant, Oak Ridge, Tennessee.
Mr. Moore has worked with the newly recruited team at BioLargo Engineering Science & Technologies for the past 10 plus years while working on behalf of CB&I. Backgrounds for the other employees of BioLargo Engineering can be found here: www.BioLargoEngineering.com
Mr. Moore added, “BioLargo’s various technologies have an important and significant commercial opportunity to serve clients around the world. Our entire team is excited to be part of such an innovative and purposeful company as BioLargo.”
To help provide growth capital to the Company and assist in the new venture, BioLargo has entered into a purchase agreement for up to $10 million of equity capital, subject to certain terms and conditions. According to the terms of this purchase agreement, and subject to a registration statement being filed and declared effective by the Securities and Exchange Commission, BioLargo will have the sole discretion to sell common stock to LPC over a 36-month period at times that are controlled by BioLargo and in amounts as described in the purchase agreement. No warrants, derivatives, financial or business covenants are associated with the agreement and LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging in BioLargo’s common stock. 
A more detailed description of the purchase agreement is set forth in BioLargo’s Current Report on Form 8-K previously filed with the SEC.
Calvert concluded, “we are surrounding our breakthrough science and technology with even more world-class talent and important capital resources to usher in meaningful technical advancements to Make Life Better Around the World. We are thankful for Lincoln Park’s confidence in us.”
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.
About BioLargo, Inc. 
BioLargo, Inc. is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.
About Lincoln Park Capital Fund, LLC
LPC is an institutional investor headquartered in Chicago, Illinois which manages a portfolio of investments in public and private entities.  These investments are in a wide range of companies and industries emphasizing life sciences, specialty financing, cleantech, energy, real estate and technology.  LPC’s investments range from multiyear financial commitments to fund growth to special situation financings to long-term strategic capital offering companies certainty, flexibility and consistency.  For more information, visit www.lpcfunds.com.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K.


Wednesday, 6 September 2017

Commercial Validation Trial Results Confirm BioLargo’s Advanced Oxidation System (AOS) as High Performance, Cost-Effective Water Treatment System


By: Tamarack Advisors (Link Here)

BioLargo, Inc. (OTC: BLGO) held its third annual “AOS technical symposium” last month, hosting a group of scientists, collaborators, water industry experts, and government representatives, according to a recent post on the company blog. Prior AOS symposiums have updated stakeholders on the company’s progress with their innovative technologies for high performance, low cost, water treatment. Held at the University of Alberta and a nearby conference center, this year was different because it included commercial validation trial results with actual wastewater provided by prospective clients.
 
AOS Test Model
Commercial Validation Studies 

Once again BioLargo scientists showcased extraordinary performance data from its Advanced Oxidation System (AOS). The event highlighted data compiled with a leading water engineering firm as well as proof-of-claim studies conducted by internal team members and independent researchers from North America and Europe. More than 30 scientists and collaborators were a part of these studies, all of which were funded in part by the company’s public funding portfolio, which includes 35 Canadian and US government grants. BioLargo management also commented that many of these studies are planned to be included in scientific journal publications in the future.

The Enormous Need For Clean and Safe Water
To understand the significance of these validated results, it is important to recognize that as much as existing water treatment technologies have great value and have saved millions of lives, they are still in many ways insufficient because often they fall short of their objective to provide clean and safe water. For example, after examining data from more than 36,000 water samples collected nationwide by the U.S. Environmental Protection Agency from 2013 to 2015, Harvard researchers found unsafe levels of toxic chemicals in the drinking water of 33 states. In 2016, a USA Today Investigation reported that after analyzing samples from 2012 through 2015, unsafe levels of lead were found in drinking water samples in all 50 States.

Global Water Intelligence estimates the annual global water market to be $862 billion. Goldman Sachs calls water “the petroleum for the next century” adding, “investors who know how to play the infrastructure boom will reap huge rewards.” With global water consumption doubling every 20 years, they predict that by 2025 about one third of the global population will not have access to adequate drinking water.

On August 1, 2016, the EPA increased fines for clean water violations. Regulators hope that the increased fines will help make compliance a priority. As violations trigger steeper penalties and fines, and in some cases, criminal prosecution, the motivation to adopt high performance clean water technologies such as the AOS is likely to increase.

BioLargo’s AOS Outperformed Current Best in Class Water Treatment Systems
The most attention-getting results at the symposium came with the AOS performance data for treating problematic industrial water samples that was done in collaboration with an independent and leading water engineering firm. The team tested wastewater from a poultry processing facility, a dairy farm, and a major west coast wastewater treatment facility. These industry-provided waste waters were then treated with a bench-scale AOS system conducted by the independent engineering firm. The results were highly promising with the AOS system consistently outperforming disinfection rates of the current best-in-class water treatment systems, including UV and ozone.

Result were also shared at the symposium that show the AOS can eliminate some difficult-to-treat micro pollutants, including pharmaceutical residues that are a growing concern the world over. According to the Scientific American, “Although millions of people flush unused medications down the toilet and discharge them in bodily waste, sewage treatment plants and septic systems are not required to deal with such contaminants and this may be contaminating the drinking water of 40 million Americans.”

Promising proof-of-claim results were also presented for the concurrent removal of BOD (Biological Oxygen Demand) with high-level disinfection, a remarkable and rare value proposition for advanced oxidation water treatment technologies.


Flexible Designs for the AOS Advanced Water Treatment System
BioLargo also presented images of two future designs highlighting a fluidized bed (low-pressure, low-footprint), as well as an array configuration of AOS columns to manage large volumes of water based on the current column design used in testing.



AOS- Mini Solar Powered
'low power and design flexibility'
One of the highlights of the symposium was the demonstration of what the company called the “Mini-AOS” – a small solar power water purification unit.  The World Health Organization claims more than 2.1 billion people lack safe drinking water at home. If put into production this invention has the potential to save countless lives and make clean drinking water available at affordable prices. The AOS-Mini was presented to the attendees to demonstrate the incredibly low power required to run the AOS as well as the flexible design choices available for the system.


Large Array AOS Scalable to 500 GPM (left) and Fluidized Bed, Low-Pressure Low-Footprint AOS System for Large Volumes (below)

We asked BioLargo’s President & CEO, Dennis P. Calvert to help elaborate on the significance of the results and what they mean for the company. He stated, “Our AOS features extremely high oxidation potential as well as extremely high reduction in a single continuous pass. The electro chemical reaction of the AOS produces extremely high rates of disinfection, which have been called ‘unprecedented’, while requiring very low levels of energy. This translates to a water treatment system with low operating expenses for eliminating hard-to-manage contaminants. Its high reduction functionality also means that it can potentially also be used to recover and remove valuable waste stream components for re-use.  Our work in this area is continuing. We project that the capital cost of building AOS units for clients will compete favorably when compared with similar technologies like carbon towers, ozone or UV. So, the AOS will get the job done, while saving our customers money. Extracting valuable waste stream components could add a whole new valuable revenue stream for the AOS. While there is engineering work to do, the results prove that the AOS works. It can do what other technologies cannot, and it can save clients real money. This combination of features makes the AOS a winner!”

With critical commercial validation studies completed, BioLargo reports they are now ready to begin working with engineers, strategic partners and customers to build commercial pilot prototypes. According to Calvert, “Stay tuned for more information as the company pushes ahead in these areas”.

The company’s Chief Science Officer, Kenneth R. Code pointed out, “With continued validation from academics and in close collaboration with water engineers in North America, our science is continually proving effective and that it can offer a low-cost alternative to incumbent technologies. Data continue to point to the AOS as one of the best in class water treatment solution. We are poised to advance our system with engineering for commercial on-site trials.”

About BioLargo, Inc.
BioLargo, Inc. (BLGO) is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.

Legal Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please 

widget